Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jubilant Profits Spurred By Foreign Business

This article was originally published in PharmAsia News

Executive Summary

Buoyed chiefly by earnings from its foreign businesses, India's pharmaceuticals and chemicals major Jubilant Organosys reported a net profit of 4 billion rupees ($98 million) for the year ending March 31

You may also be interested in...



Indian Companies Look To Emphasize Drug Technology Advantages Rather Than Cost Savings With MNCs

FRANKFURT, Germany - Indian drug companies are sharpening their focus on technology to take contract manufacturing and service capabilities to a stage where multinational companies will look to partner for reasons other than cost savings

Indian Companies Look To Emphasize Drug Technology Advantages Rather Than Cost Savings With MNCs

FRANKFURT, Germany - Indian drug companies are sharpening their focus on technology to take contract manufacturing and service capabilities to a stage where multinational companies will look to partner for reasons other than cost savings

PharmAsia News India Pharma Roundup: Lupin, Strides Arcolab, GSK India, Nicholas Piramal, Jubilant

NEW DELHI - India's fifth largest generic drug firm Lupin wants to buy other drug formulation companies in the U.S., Latin America, Southeast Asia and the Middle East this year to expand its presence overseas its chairman said after announcing a sharp, but expected, drop in earnings for the fourth quarter ended March 31

Related Content

UsernamePublicRestriction

Register

SC068510

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel